logo
[breadcrumb_custom]

Tag: NASDAQ:CGEM

OPEN Stock
Industry

CGEM’s Stock Market Adventure: 87.03% YTD Growth Amidst Volatility

Investors’ outlook regarding the stock price performance over the year has been a mixed bag, with a range of optimism to pessimism depending on their perspective. The index has shown a price gain of 87.03% this year. Over the last six months, there has been a weaker performance of 116.57%. The price of CGEM fallen by 19.64% during the last 30 days period. For the last 5-days stocks have improved 11.91%. Cullinan Oncology Inc had a pretty favorable run when it comes to the market performance. Over the past year, the company’s stock reached a high of $19.68 on 04/16/24,

HCCC Stock
Finance

Cullinan Oncology Inc (CGEM) Stock: A Year of Highs and Lows

Examining a stock’s 52-week price history, encompassing its low and high prices, can reveal much about its existing condition and potential future trajectory. Cullinan Oncology Inc’s current trading price is -16.97% away from its 52-week high, while its distance from the 52-week low is 113.87%. The stock’s price range over this period has fluctuated between $7.64 and $19.68. The company, operating within the financial sector, had a trading volume of approximately 0.47 million for the day, which was noticeably higher than the average daily share volume of 0.41 million over the last 3 months. Cullinan Oncology Inc saw a rather

ZM Stock
Finance

Anchoring Your Portfolio: Is CGEM Stock a Safe Harbor?

Cullinan Oncology Inc experienced a rather steady stock market performance. The highest value in the past year was recorded at $19.68 on 02/12/24 and the lowest value was $7.64 on 12/12/23. 52-week price history of CGEM Stock A stock’s 52-week high and low prices can reveal much about its current status and future trajectory. Cullinan Oncology Inc’s current trading price is -16.92% away from its 52-week high, while its distance from the 52-week low is 114.01%. The stock’s price range during this period has spanned from $7.64 to $19.68. In the Healthcare sector, the Cullinan Oncology Inc’s shares surpassed a